RT Journal Article
SR Electronic
T1 Distinct genomic profiles are associated with treatment response and survival in ovarian cancer
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.04.20118976
DO 10.1101/2020.06.04.20118976
A1 de Witte, Chris J.
A1 Kutzera, Joachim
A1 van Hoeck, Arne
A1 Nguyen, Luan
A1 Boere, Ingrid A.
A1 Jalving, Mathilde
A1 Ottevanger, Petronella B.
A1 van Schaik - van de Mheen, Christa
A1 Stevense, Marion
A1 Kloosterman, Wigard P.
A1 Zweemer, Ronald P.
A1 Cuppen, Edwin
A1 Witteveen, Petronella O.
YR 2020
UL http://medrxiv.org/content/early/2020/06/05/2020.06.04.20118976.abstract
AB The majority of patients with ovarian cancer ultimately develop recurrent chemotherapy resistant disease. Treatment stratification is mainly based on histological subtype and stage, prior response to platinum-based chemotherapy and time to recurrent disease. Here, we integrated clinical treatment, treatment response and survival data with whole genome sequencing profiles of 132 solid tumor biopsies of metastatic epithelial ovarian cancer to explore genome-informed stratification opportunities. Samples from primary and recurrent disease harbored comparable numbers of single nucleotide variants and structural variants. Mutational signatures represented platinum exposure, homologous recombination deficiency and aging. Unsupervised hierarchical clustering based on genomic input data identified specific ovarian cancer subgroups, characterized by homologous recombination deficiency, genome stability and duplications. The clusters exhibited distinct response rates and survival probabilities which according to our analysis could potentially be improved by genome-informed treatment stratification.Competing Interest StatementM. Jalving reports the following competing interests: Advisory Board, honoraria to institution: Merck, BMS, Novartis, Pierre Fabre, Tesaro, AstraZeneca. Clinical studies: BMS, AbbVie, Merck, Cristal Therapeutics. The other authors declare no competing interests.Funding StatementThis work was supported by the Gieskes Strijbis Foundation (1816199) and the Dutch Cancer Society (UU2015-7743).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board of the UMC Utrecht and the Netherlands Cancer Institute (IRB UMCU/NCI).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data described in this study are freely available for academic use from the Hartwig Medical Foundation through standardized procedures and request forms that can be found at https://www.hartwigmedicalfoundation.nl/en/appyling-for-data/.